文献速递瓣膜病与结构性心脏病血脂与心血管预防

高敏C反应蛋白预测成人先天性心脏病临床事件的前瞻性队列研究

Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank.
PubMed 文献 · Eur Heart J · 2018-01-01

该前瞻性队列研究纳入707例门诊成人先天性心脏病患者,测量血清高敏C反应蛋白(hsCRP)并随访平均815天。结果显示hsCRP最高四分位(≥2.98 mg/L)者全因死亡或非择期心血管住院风险显著增加(30.5% vs 11.3%,调整HR=2.00),全因死亡风险亦显著升高(11.9% vs 1.5%,调整HR=4.23)。

要点

  • hsCRP升高与成人先天性心脏病患者功能状态差和运动能力下降相关。
  • hsCRP≥2.98 mg/L者全因死亡或非择期心血管住院风险增加2倍。
  • hsCRP≥2.98 mg/L者全因死亡风险增加4.23倍。

核心结论

  • 成人先天性心脏病患者hsCRP升高不仅功能状态和运动能力更差,而且死亡或非择期心血管住院风险更高。

研究设计与样本

  • 前瞻性队列研究,纳入707例门诊成人先天性心脏病患者(年龄39±14岁,49%女性),主要在转诊中心入组,2012至2016年间测量血清hsCRP并结合临床评估。

主要发现

  • 平均随访815±536天,114例(16%)发生主要复合终点,包括29例死亡。
  • hsCRP最高四分位(≥2.98 mg/L)与较低三个四分位相比,主要终点发生率30.5% vs 11.3%,调整HR=2.00(95%CI 1.35-2.97;P=0.0006)。
  • hsCRP最高四分位与较低三个四分位相比,全因死亡率11.9% vs 1.5%,调整HR=4.23(95%CI 1.87-9.59;P=0.0006)。
  • hsCRP升高与成人先天性心脏病各亚组及其他患者特征的不良结局相关。
  • 较高的hsCRP与功能状态指标(纽约心脏协会心功能分级和峰值摄氧量)及合并症如房性心律失常强烈相关。

临床怎么用

  • 在成人先天性心脏病门诊患者中,可考虑检测hsCRP以协助风险分层,尤其关注hsCRP≥2.98 mg/L者。

局限性

  • 研究主要在转诊中心入组,结果外推需谨慎。
  • 炎症在成人先天性心脏病病理生理中的作用尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Despite the well-defined association of high-sensitivity hsCRP with cardiovascular outcomes in apparently healthy adults and those with acquired heart disease, the relevance of this inflammatory marker in adults with congenital heart disease (ACHD) remains unclear. We aimed to examine the clinical correlates and prognostic value of high-sensitivity C-reactive protein levels in ACHD. METHODS AND RESULTS: We conducted a prospective cohort study of (n = 707) outpatient ACHD (age 39 ± 14 years, 49% women), enrolled mainly at a referral centre, who had serum hsCRP measured in conjunction with a clinical assessment between 2012 and 2016. We analysed clinical correlates of hsCRP and its association with adverse events including the primary combined outcome of all-cause mortality or non-elective cardiovascular hospitalization. Higher hsCRP was strongly associated with measures of functional status including New York Heart Association class and peak V̇O2, and with comorbidities such as atrial arrhythmia. During average follow-up of 815 ± 536 days, 114 patients (16%) experienced the primary outcome, including 29 deaths. Having elevated hsCRP, in the highest (≥2.98 mg/L) compared with the lower three quartiles, conferred increased risk for the primary outcome [30.5% vs. 11.3%, adjusted hazard ratio (HR) = 2.00, 95% confidence interval (CI) 1.35-2.97; P = 0.0006] and all-cause mortality (11.9% vs. 1.5%, adjusted HR = 4.23, 95% CI 1.87-9.59; P = 0.0006). Elevated hsCRP was associated with adverse outcomes across ACHD subgroups and other patient characteristics. CONCLUSION: Adults with congenital heart disease with elevated hsCRP have not only worse functional status and exercise capacity, but also greater risk for death or non-elective cardiovascular hospitalization. Further study is warranted to characterize the role of inflammation in the pathophysiology of ACHD.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Opotowsky AR, Valente AM, Alshawabkeh L, et al. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. Eur Heart J. 2018. PMID: 30010900. doi:10.1093/eurheartj/ehy362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。